Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [HEALTH]
2 clusters · 7 sources · 15 days · First seen · Last updated
Sacituzumab tirumotecan endometrial cancer research
Overview
Clinical trial results for the experimental antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) indicate significant improvements for patients with advanced or recurrent endometrial cancer. Data from the Phase 3 TroFuse-005 international trial, involving 776 women, showed that sac-TMT reduced the risk of death by 32% and the risk of disease progression or death by 41% compared to standard chemotherapy.
Key metrics from the study include a median overall survival of 19 months for the sac-TMT group versus 12 months for the control group, and an objective response rate of 35.1% compared to 17.3% in the chemotherapy group. The drug functions by targeting the Trop2 protein to deliver chemotherapy directly to tumor cells. Reported side effects include oral mucositis and low blood counts.
Entities
ESMO · sacituzumab tirumotecan · American Society for Reproductive Medicine · American Cancer Society · World Health Organization
Timeline
-
[HEALTH] 7 sourcesScientific research explores brain health, nutrition, and cognitive function
New research examines the impact of Omega-3 supplements on memory, the metabolic causes of mental fatigue, the role of Vitamin B12 in brain health, and the therapeutic potential of psilocybin.
-
[HEALTH] 17 sourcesSacituzumab tirumotecan shows promise in treating advanced endometrial cancer
A Phase 3 trial of sacituzumab tirumotecan (sac-TMT) shows a 32% reduction in death risk for patients with advanced or recurrent endometrial cancer compared to standard chemotherapy.
Sources
bunte.de · hna.de · kreiszeitung.de · leinetal24.de · op-online.de · tz.de · whudat.de